Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Gi Reviewers LLC

Neither a doctor nor a teaching hospital

Research payments

$6,600,831

1,632 payments

Through program year 2025, Gi Reviewers LLC is reported as receiving $6,600,831 in research payments, across 1,632 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $681,868 198
2024 Research $2,797,984 664
2023 Research $1,362,920 299
2022 Research $695,433 208
2021 Research $260,594 122
2020 Research $538,316 64
2019 Research $263,716 77

Breakdown

Who paid Research payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $4,146,615 993 payments
  2. AstraZeneca UK Limited $1,049,095 67 payments
  3. Ipsen Innovation $486,477 64 payments
  4. Braintree Laboratories, Inc. $298,370 23 payments
  5. Amgen Inc. $235,006 37 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $95,831 48 payments
  7. BioNTech SE $93,885 135 payments
  8. AbbVie, Inc. $86,389 137 payments
  9. Ipsen Biopharmaceuticals, Inc $24,080 9 payments
  10. Eli Lilly and Company $19,320 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomised, Double-Blind, Parallel Group Phase III Study to Assess T $1,644,807 435 payments
  2. A Phase 2, Randomized, Open-Label, Platform Study Utilizing A Master P $867,794 64 payments
  3. A Randomised, Double-Blind, Placebo Controlled, Parallel Group Phase I $594,146 160 payments
  4. A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study Of Benralizumab in Patients with Severe Nasal Polyposis OSTRO $504,865 20 payments
  5. A Phase 2 Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Paediatric and Adult Participants. $486,477 64 payments
  6. A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Thera $473,674 80 payments
  7. A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo- Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients with Eosinophilic Chronic Rhinosinusitis with Nasal Polyps (ORCHID) $346,155 31 payments
  8. A Phase 2, Single-Arm, Open-Label Study With Dostarlimab Monotherapy I $215,620 118 payments
  9. Bli4900-301 $151,450 11 payments
  10. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter S $137,013 39 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record